Current Fundamentals: AnaptysBio (NASDAQ: ANAB)

EPS growth is an important number as it indicates the future prospects of AnaptysBio. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -32.20% over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at AnaptysBio.

AnaptysBio is in the healthcare sector and biotechnology industry. The company CEO is Hamza Suria. AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-ntibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

Previous Intraday Performance:

The ANAB shares had a previous change of 3.68% which opened at 66.32 and closed at 68.76. It moved to an intraday high of 69.93 and a low of 65.06.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, ANAB shares returned 9.14% and in the past 30 trading days it returned 13.58%. Over three months, it changed -1.22%. In one year it has changed -37.78% and within that year its 52-week high was 134.00 and its 52-week low was 54.26. ANAB stock is 26.72% above its 52 Week Low.

Our calculations result in a 200 day moving average of 78.86 and a 50 day moving average of 68.15. Right now, ANAB stock is trading -12.81% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa


The company has a market cap of $1.8b with 26.8m shares outstanding and a float of 26.2m shares. Trading volume was 160,102 shares and has experienced an average volume of 319,959 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for AnaptysBio was -1.61 which ended on 31st of December 2017. Based on 6 analyst estimates, the consensus EPS for the next quarter is -0.91.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.66
06-30-2018:  -0.57
03-31-2018:  -0.63
12-31-2017:  -0.30

Indicators Also to Watch:

Based on the latest filings, there is 173.20% of institutional ownership.

I calculated the beta to be 2.38

PR Newswire:  SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -17.17%, return on assets is -16.01%, price-to-sales is 354.83 and price-to-book is 3.68.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Tags: , , ,

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *